Medidata and Cognizant have formed a multi-year strategic alliance to develop new solutions for pharmaceutical, biotech, medical device companies, contract research organizations (CROs), sites, and investigators.
Scott Hoffman, senior vice president, global services, solutions and alliances at Medidata, said the goal is to “empower life science organizations of all sizes and therapeutic areas to digitally transform their research and commercialization.”
“As clinical trials become more complex, the key to success is eliminating operational burdens so that researchers can focus on the science of a study,” he told us.
Under the agreement, the professional services company Cognizant will develop managed services and solutions specific to Medidata’s platform. As part of this, Medidata Site Payments also will connect with Cognizant’s Shared Investigator Platform (SIP).
Hoffman explained that the combination of professional services with technology and data assets will remove operational barriers, enabling sponsors and CROs to optimize and expand their studies.
“For example, some sponsors and CROs may hesitate to adopt a modern randomization and trial supply management (RTSM) solution without built-in services such as biostats, drug supply management and help desks,” he said.
“Wrapping Cognizant services around Medidata’s RTSM solution eliminates this challenge and drives adoption of this critical tool for improving data quality and reducing risk.”
